Patents by Inventor Jonathan Drew Smith
Jonathan Drew Smith has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8455186Abstract: A method of determining the presence or absence of a target microorganism in a sample to be tested, the method comprising: combining with the sample an amount of bacteriophage capable of attaching to the target microorganism to create a bacteriophage exposed sample, and a substance which enhances bacteriophage amplification or sensitivity; providing conditions to the bacteriophage-exposed sample sufficient to allow the bacteriophage to infect the microorganism; and assaying the bacteriophage-exposed sample to detect the presence or absence of a bacteriophage marker to determine the presence or absence of the target microorganism.Type: GrantFiled: June 13, 2008Date of Patent: June 4, 2013Assignee: MicroPhage™ IncorporatedInventors: Jonathan Drew Smith, Jon C. Rees, Duane Bush, Breanna Leigh Dreiling, Maria Izzo, Breanna Christine Smith, Bernard Sportmann, Tiffany Steinmark, Richard Proctor
-
Patent number: 8216780Abstract: A method of determining the presence or absence of a target microorganism in a sample to be tested, the method comprising: (a) combining with the sample an amount of bacteriophage capable of attaching to the target microorganism to create a bacteriophage-exposed sample; (b) providing conditions to the bacteriophage-exposed sample sufficient to allow the bacteriophage to attach to the target microorganism while inhibiting phage replication in a potentially cross-reactive, non-target microorganism; and (c) assaying the bacteriophage-exposed sample to detect the presence or absence of a bacteriophage marker to determine the presence or absence of the target microorganism; wherein the amount of the bacteriophage is between 10% to 70% of the threshold number of bacteriophage that the assay can detect, or between 1×106 pfu/mL and 7×106 pfu/mL.Type: GrantFiled: June 2, 2009Date of Patent: July 10, 2012Assignee: MicroPhage (TM) IncorporatedInventors: Jonathan Drew Smith, Breanna Leigh Dreiling, Breanna Christine Smith, John H. Wheeler
-
Patent number: 8071288Abstract: The present invention provides novel methods and reagents for detecting the binding of protein targets to nucleic acid ligands. Using Universal Protein Stains (UPS), proteins bound by nucleic acid ligands may be labeled with a detectable moiety. The methods and reagents are particularly useful for the detection of protein targets bound to multiplexed arrays of nucleic acid ligands. The present invention also provides novel methods for the multiplexed evaluation of photocrosslinking nucleic acid ligands. The methods allow one simultaneously to: (1) evaluate the performance (dynamic range) of a plurality of photocrosslinking nucleic acid ligands; and (2) assess the specificity of each photocrosslinking nucleic acid ligand for its cognate target protein. Photocrosslinking nucleic acid ligands with the most desirable properties can then be selected for use in diagnostic and prognostic medical assays.Type: GrantFiled: February 12, 2008Date of Patent: December 6, 2011Assignee: SomaLogic, Inc.Inventors: Larry Gold, Jonathan Drew Smith, Dominic Zichi, Daniel J. Schneider, Chad Greef
-
Publication number: 20100196877Abstract: A method of determining the presence or absence of a target microorganism in a sample to be tested, the method comprising: combining with the sample an amount of bacteriophage capable of attaching to the target microorganism to create a bacteriophage exposed sample, and a substance which enhances bacteriophage amplification or sensitivity; providing conditions to the bacteriophage-exposed sample sufficient to allow the bacteriophage to infect the microorganism; and assaying the bacteriophage-exposed sample to detect the presence or absence of a bacteriophage marker to determine the presence or absence of the target microorganism.Type: ApplicationFiled: June 13, 2008Publication date: August 5, 2010Applicant: MicroPhage IncorporatedInventors: Jonathan Drew Smith, Jon C. Rees, Duane Bush, Breanna Leigh Dreiling, Maria Izzo, Breanna Christine Smith, Bernard Sportmann, Tiffany Steinmark, Richard Proctor
-
Publication number: 20090286232Abstract: A method of determining the presence or absence of a target microorganism in a sample to be tested, the method comprising: (a) combining with the sample an amount of bacteriophage capable of attaching to the target microorganism to create a bacteriophage-exposed sample; (b) providing conditions to the bacteriophage-exposed sample sufficient to allow the bacteriophage to attach to the target microorganism while inhibiting phage replication in a potentially cross-reactive, non-target microorganism; and (c) assaying the bacteriophage-exposed sample to detect the presence or absence of a bacteriophage marker to determine the presence or absence of the target microorganism; wherein the amount of the bacteriophage is between 10% to 70% of the threshold number of bacteriophage that the assay can detect, or between 1×106pfu/mL and 7×106pfu/mL.Type: ApplicationFiled: June 2, 2009Publication date: November 19, 2009Applicant: MicroPhage™ IncorporatedInventors: Jonathan Drew Smith, Breanna Leigh Dreiling, Breanna Christine Smith, John H. Wheeler
-
Publication number: 20080160535Abstract: The present invention provides novel methods and reagents for detecting the binding of protein targets to nucleic acid ligands. Using Universal Protein Stains (UPS), proteins bound by nucleic acid ligands may be labeled with a detectable moiety. The methods and reagents are particularly useful for the detection of protein targets bound to multiplexed arrays of nucleic acid ligands. The present invention also provides novel methods for the multiplexed evaluation of photocrosslinking nucleic acid ligands. The methods allow one simultaneously to: (1) evaluate the performance (dynamic range) of a plurality of photocrosslinking nucleic acid ligands; and (2) assess the specificity of each photocrosslinking nucleic acid ligand for its cognate target protein. Photocrosslinking nucleic acid ligands with the most desirable properties can then be selected for use in diagnostic and prognostic medical assays.Type: ApplicationFiled: February 12, 2008Publication date: July 3, 2008Applicant: SOMALOGIC, INC.Inventors: Larry Gold, Jonathan Drew Smith, Dominic Zichi, Daniel J. Schneider, Chad Greef
-
Patent number: 6730482Abstract: This invention is directed towards a method for obtaining nucleic acid ligands against target proteins without directly purifying the target proteins. The method used in the invention is called SELEX, which is an acronym for Systematic Evolution of Ligands by EXponential enrichment. The nucleic acid ligands of the invention are useful as diagnostic and therapeutic agents for diseases in which the targets proteins play a causative role.Type: GrantFiled: March 12, 2002Date of Patent: May 4, 2004Assignee: SomaLogic, Inc.Inventors: Larry Gold, Dominic A. Zichi, Jonathan Drew Smith
-
Patent number: 6706482Abstract: The invention provides method for producing nucleic acid ligands that generate a signal, or cause a decrease in the level of a signal, in the presence of a target molecule or an environmental stimulus. The methods of the instant invention are collectively termed Conditional SELEX. The nucleic acid ligands of the instant invention are useful in any application where it is desirable to measure the concentration of a target molecule or detect and quantitate an environmental stimulus.Type: GrantFiled: December 27, 2002Date of Patent: March 16, 2004Assignee: Somalogic, Inc.Inventors: Jonathan Drew Smith, Larry Gold
-
Publication number: 20030087301Abstract: The invention provides method for producing nucleic acid ligands that generate a signal, or cause a decrease in the level of a signal, in the presence of a target molecule or an environmental stimulus. The methods of the instant invention are collectively termed Conditional SELEX. The nucleic acid ligands of the instant invention are useful in any application where it is desirable to measure the concentration of a target molecule or detect and quantitate an environmental stimulus.Type: ApplicationFiled: December 27, 2002Publication date: May 8, 2003Applicant: SomaLogic, Inc.Inventors: Jonathan Drew Smith, Larry Gold
-
Publication number: 20030054360Abstract: The present invention includes a method and device for performing the automated SELEX process, including automated photoSELEX process embodiments, and automated affinity SELEX process embodiments. The automated photoSELEX embodiments included an embodiment wherein target protein and nucleic acid ligands are photocrosslinked in solution. The steps of the SELEX process are performed at one or more work stations on a work surface by a robotic manipulator controlled by a computer.Type: ApplicationFiled: November 21, 2001Publication date: March 20, 2003Inventors: Larry Gold, Dominic A. Zichi, Jonathan Drew Smith, Daniel J. Schneider
-
Publication number: 20030044818Abstract: This invention is directed towards a method for obtaining nucleic acid ligands against target proteins without directly purifying the target proteins. The method used in the invention is called SELEX, which is an acronym for Systematic Evolution of Ligands by EXponential enrichment. The nucleic acid ligands of the invention are useful as diagnostic and therapeutic agents for diseases in which the targets proteins play a causative role.Type: ApplicationFiled: March 12, 2002Publication date: March 6, 2003Inventors: Larry Gold, Dominic A. Zichi, Jonathan Drew Smith
-
Patent number: 6506887Abstract: The invention provides method for producing nucleic acid ligands that generate a signal, or cause a decrease in the level of a signal, in the presence of a target molecule or an environmental stimulus. The methods of the instant invention are collectively termed Conditional SELEX. The nucleic acid ligands of the instant invention are useful in any application where it is desirable to measure the concentration of a target molecule or detect and quantitate an environmental stimulus.Type: GrantFiled: July 29, 1999Date of Patent: January 14, 2003Assignee: SomaLogic, IncorporatedInventors: Jonathan Drew Smith, Larry Gold
-
Patent number: 6458539Abstract: Methods are described for the identification and preparation of high-affinity nucleic acid ligands to bFGF. Included in the invention are specific DNA ligands to bFGF identified by the photoSELEX method. Also included is a method for determining the position of a nucleic acid ligand-protein photoadduct.Type: GrantFiled: July 19, 2000Date of Patent: October 1, 2002Assignee: Somalogic, Inc.Inventors: Larry Gold, Jonathan Drew Smith, Tad Koch, Mace Golden
-
Publication number: 20020102599Abstract: Methods are provided for the production of nucleic acid ligands against target molecules using a procedure known as Transcription-free Systematic Evolution of Ligands by EXponential enrichment (Transcription-free SELEX). The Transcription-free SELEX method assembles nucleic acid ligands from fragments of synthetic nucleic acids by annealing those fragments to a complementary template, and then ligating the fragments together.Type: ApplicationFiled: March 22, 2002Publication date: August 1, 2002Applicant: Gilead SciencesInventors: Jonathan Drew Smith, Larry Gold
-
Patent number: 6387620Abstract: Methods are provided for the production of nucleic acid ligands against target molecules using a procedure known as Transcription-free Systematic Evolution of Ligands by EXponential enrichment (Transcription-free SELEX). The Transcription-free SELEX method assembles nucleic acid ligands from fragments of synthetic nucleic acids by annealing those fragments to a complementary template, and then ligating the fragments together.Type: GrantFiled: July 28, 1999Date of Patent: May 14, 2002Assignee: Gilead Sciences, Inc.Inventors: Jonathan Drew Smith, Larry Gold
-
Patent number: 6376190Abstract: This invention is directed towards a method for obtaining nucleic acid ligands against target proteins without directly purifying the target proteins. The method used in the invention is called SELEX, which is an acronym for Systematic Evolution of Ligands by EXponential enrichment. The nucleic acid ligands of the invention are useful as diagnostic and therapeutic agents for diseases in which the targets proteins play a causative role.Type: GrantFiled: September 22, 2000Date of Patent: April 23, 2002Assignee: SomaLogic, Inc.Inventors: Larry Gold, Dominic A. Zichi, Jonathan Drew Smith
-
Publication number: 20020038000Abstract: A method for preparing polypeptide ligands of target molecules wherein candidate mixtures comprised of ribosome complexes or mRNA&Circlesolid;polypeptide copolymers are partitioned relative to their affinity to the target and amplified to create a new candidate mixture enriched in ribosome complexes or mRNA&Circlesolid;polypeptide copolymers with an affinity to the target.Type: ApplicationFiled: February 22, 2001Publication date: March 28, 2002Inventors: Larry Gold, Craig Tuerk, David Pribnow, Jonathan Drew Smith
-
Patent number: 6194550Abstract: A method for preparing polypeptide ligands of target molecules wherein candidate mixtures comprised of ribosome complexes or mRNA•polypeptide copolymers are partitioned relative to their affinity to the target and amplified to create a new candidate mixture enriched in ribosome complexes or mRNA•polypeptide copolymers with an affinity to the target.Type: GrantFiled: November 23, 1998Date of Patent: February 27, 2001Inventors: Larry Gold, Craig Tuerk, David Pribnow, Jonathan Drew Smith
-
Patent number: 5843701Abstract: A method for preparing polypeptide ligands of target molecules wherein candidate mixtures comprised of ribosome complexes or mRNA.multidot.polypeptide copolymers are partitioned relative to their affinity to the target and amplified to create a new candidate mixture enriched in ribosome complexes or mRNA.multidot.polypeptide copolymers with an affinity to the target.Type: GrantFiled: January 31, 1992Date of Patent: December 1, 1998Assignee: NeXstar Pharmaceticals, Inc.Inventors: Larry Gold, Craig Tuerk, David Pribnow, Jonathan Drew Smith